Pilar S. H.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase 3 Multicenter Randomized Study of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in High-Risk HER2-Positive Breast Cancer with Residual Disease
- Adjuvant Pembrolizumab and Paclitaxel Versus Surveillance in Early Triple-Negative Breast Cancer with High Stromal Tumor-Infiltrating Lymphocytes
- Phase III Randomized Trial of Palbociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR+/HER2- Early Breast Cancer
Data & Insights
Has run more than one trial at 158 of 437 partner sites.
Specializations
Breast Oncology
Breast cancer is a central area of interest, with activity spanning early-stage, locally advanced, and metastatic disease. The portfolio includes hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative breast cancer, alongside biomarker-defined populations such as PIK3CA-mutated and BRCA-altered disease.
- Early breast cancer
- Metastatic breast cancer
- Triple-negative breast cancer
- HER2-directed treatment
- Endocrine-responsive disease
Therapeutic interest also extends to neoadjuvant and adjuvant strategies, post-endocrine resistance settings, and treatment combinations designed to refine precision care in breast oncology.
Hematologic Malignancies and Cellular Therapy
Research involvement covers a broad range of hematologic cancers, including multiple myeloma, acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive lymphomas. The clinical focus includes relapsed, refractory, and newly diagnosed disease across both adult and pediatric populations.
- Multiple myeloma
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Cell therapy in B-cell lymphoma
Additional interest includes autologous stem cell transplant, CAR-T therapy, and immune-based approaches for difficult-to-treat B-cell malignancies.
Cardiovascular Disease and Thromboinflammation
Clinical research activity includes atherosclerotic cardiovascular disease, myocardial infarction, heart failure, atrial fibrillation, and cardiomyopathy, with attention to both prevention and treatment of advanced cardiac disease. The scope also includes stroke prevention and residual risk reduction in high-risk cardiovascular populations.
- Atherosclerotic cardiovascular disease
- Heart failure
- Atrial fibrillation
- Cardiomyopathy
- Stroke prevention
Therapeutic domains further include lipid management, antithrombotic therapy, and inflammatory cardiovascular risk, reflecting a strong interest in cardiovascular innovation.
Gynecologic and Gastrointestinal Oncology
Interest extends to ovarian cancer, endometrial cancer, cervical cancer, gastric cancer, pancreatic adenocarcinoma, and colorectal cancer. The portfolio includes both advanced and recurrent disease, with emphasis on tumors that remain challenging after standard treatment.
- Ovarian cancer
- Endometrial cancer
- Cervical cancer
- Gastric cancer
- Colorectal cancer
Relevant therapeutic areas include antibody-drug conjugates, PARP inhibition, and maintenance strategies in gynecologic and digestive tract malignancies.
Autoimmune, Neurologic, and Rare Disease Therapeutics
Clinical trial involvement also covers multiple sclerosis, systemic lupus erythematosus, myelofibrosis, hemophilia, idiopathic pulmonary fibrosis, and other uncommon conditions. This includes immune-mediated, neurologic, and inherited disorders with unmet therapeutic needs.
- Multiple sclerosis
- Systemic lupus erythematosus
- Hemophilia
- Myelofibrosis
- Idiopathic pulmonary fibrosis
Therapeutic interest spans immune modulation, disease control in chronic inflammatory disorders, and targeted approaches for rare diseases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.